Stock ENVB ENVERIC BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
0.89 USD -3.26% Intraday chart for Enveric Biosciences, Inc. -9.18% -31.54%
05-08 Enveric Biosciences, Inc. Announces Signing of Non-Binding Term Sheet with Undisclosed License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids CI
03-26 Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
BU
Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology [Microdose]
PU
Enveric Biosciences : Shareholder Meeting - Form 8-K
PU
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
BU
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
BU
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
BU
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
BU
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
AQ
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
AQ
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
BU
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
BU
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
BU
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
BU
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
BU
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
BU
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
BU
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
BU
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
BU
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference
AQ
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENVB Stock
  4. News Enveric Biosciences, Inc.
  5. Press Releases